e-therapeutics plc (AIM: ETX.L) is pleased to announce a conditional offer for subscription via PrimaryBid (the “Retail Offer”) of new ordinary shares of 0.1p each in the Company (“Retail Shares”)
e-Therapeutics plc (ETX.L) COVID-19 Project Update
Oxford, UK, 8 December 2020 – e-therapeutics plc (AIM: ETX) announces the results of experimental testing on the compounds for the treatment of COVID-19 identified using its proprietary Network-driven Drug
e-Therapeutics plc (ETX.L) Expansion into RNAi and creation of SAB
Expansion to encompass RNA interference (RNAi) as a new therapeutic modality and the formation of a Scientific Advisory Board (SAB)